noom and glp-1 expands its range with 'microdose' package Noom’s New Microdose GLP-1 Program
Description
The combination has to be screened for phentermines cardiovascular contraindications and topiramates renal and cognitive effects, plus the additive nausea risk of GLP-1 plus topiramate
Hendershot, Christian S., et al
Clinically, we are seeing that some patients report a reduced sense of reward from certain behaviors
Direct clinical trials specifically testing GLP-1 agents with oral contraceptives are limited, which is why providers take a cautious approach
